Immutep Ltd IMP761 Preclinical Results In Global Webcast Transcript
Good morning, everyone. Thank you for joining us on the Immutep investor call. Clive Tompkins, I'll be your moderator today. (Operator Instructions)
Look, at this time now, I will hand over to Marc Voigt, CEO -- Immutep's CEO, to start the presentation. Over to you now, Marc.
Thank you, Clive, and welcome, everyone. We appreciate your time on the webcast today. Briefly, our forward-looking statement. Now as many of you know, Immutep is the leader in the development of LAG-3 related therapeutics. This is a very promising area of biotechnology and immunology. And one that is receiving increasing interest from Big Pharma, especially in 2018 and '19, and beyond.
In the last few years, Immutep has spoken a lot about how LAG-3 therapeutics can act in immuno-oncology as an immune stimulant. We have described our pipeline of trials with our anti-cancer drug, eftilagimod alpha or IMP321. These clinical trials include
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |